Lv11
46 积分 2024-08-19 加入
Dissolution-modulating mechanism of pH modifiers in solid dispersion containing weakly acidic or basic drugs with poor water solubility
1个月前
已完结
Materials for oral delivery of proteins and peptides
2个月前
已完结
Oral Muvalaplin for Lowering of Lipoprotein(a)
2个月前
已完结
Disposition and Absolute Bioavailability of Orally Administered Orforglipron in Healthy Participants
2个月前
已完结
Evaluating Scale-Up Rules of a High-Shear Wet Granulation Process
3个月前
已完结
FDA approved PFS-based autoinjectors: evolution, market trends, and development challenges
3个月前
已完结
Strategies for Accelerated Drug Development: An Industry Perspective Based on an IQ Consortium Survey of CMC Considerations
3个月前
已完结
Characterization of adsorption behavior by solid dosage form excipients in formulation development
4个月前
已完结
Orforglipron (LY3502970), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: A Phase 1b, multicentre, blinded, placebo‐controlled, randomized, multiple‐ascending‐dose study in people with type 2 diabetes
4个月前
已完结
Impurity Qualification Thresholds: An IQ Survey on Emerging Industry Experience with Health Authority Feedback
5个月前
已完结
皖公网安备34019202002308
